Form 4: Quest Diagnostics Executive Acquires Shares Through Dividend Reinvestment
SEC Form 4 Filing
Mark E. Delaney, SVP & Chief Commercial Officer of Quest Diagnostics, acquired 4 shares of common stock through a dividend reinvestment plan.
Summary
- On January 29, 2025, Mark E. Delaney, SVP & Chief Commercial Officer of Quest Diagnostics, acquired 4 shares of common stock.
- The shares were acquired through a dividend reinvestment plan at a price of $158.025 per share.
- Following the transaction, Delaney directly owns 5,027 shares of Quest Diagnostics common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transaction is a routine acquisition of shares through a dividend reinvestment plan.
Positives
- The acquisition of shares through a dividend reinvestment plan demonstrates the executive's confidence in the company's future.
Industry Context
Insider transactions are routinely monitored and reported to the SEC. Small acquisitions like this through dividend reinvestment plans are common and generally viewed as a neutral indicator.
Key Dates
| Date | Description |
|---|---|
| 01/29/2025 | Date of transaction: Mark E. Delaney acquired 4 shares of Quest Diagnostics common stock. |
| 01/31/2025 | Date of signature: Sean D. Mersten, Attorney in Fact for Mark E. Delaney, signed the Form 4. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.